For decades, breast cancer survivors going through menopause have been told that hormone therapy is off-limits—full stop. But new analyses and a 2025 expert consensus paper suggest that there may be ...

The risks and benefits of hormone replacement therapy use for menopausal symptoms in breast cancer survivors are examined in light of recent research.

HRT does not increase breast cancer risk in BRCA1/BRCA2 variant carriers, with lower incidence in users versus non-users. Estrogen-alone therapy is linked to reduced mortality, while estrogen plus ...

Cancer of the breast is the most commonly occurring cancer in women, and the third most common cancer overall. Incidence and mortality for this and other gynecological cancers are still increasing in ...

Israel: In women with BRCA pathogenic variants after risk-reducing bilateral oophorectomy (RRBO), estrogen-only hormone ...

RESULTS: Breast cancer patients, unwilling to trade symptom reduction for even a small increase in recurrence risk, are at substantially increased risk of death from breast cancer relative to other ...